Catalyst

Slingshot members are tracking this event:

Alexion's (ALXN) ALXN1210 in atypical Hemolytic Uremic Syndrome (aHUS) PDUFA data under priority review October 19, 2019

Source Link:
https://ir.alexion.com/news-releases/news-release-details/us-fda-accepts-supplemental-biologics-license-application-sbla

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ALXN Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 18, 2019
Occurred Source:
https://news.alexionpharma.com/press-release/product-news/alexion-receives-fda-approval-ultomiris-ravulizumab-cwvz-atypical-hemolyt
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Atypical Hemolytic Uremic Syndrome, Alxn1210
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.